7-chloro-6-methoxy-1H-benzo[d][1,3]oxazine-2,4-dione | 97927-44-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶嗪类
• 英文名称: 7-chloro-6-methoxy-1H-benzo[d][1,3]oxazine-2,4-dione
• 英文别名: 7-chloro-6-methoxy-1H-3,1-benzoxazine-2,4-dione
• CAS: 97927-44-1
• 化学式: C₉H₆ClNO₄
• 分子量: 227.604
• InChiKey: PESBODVNJSIJOY-UHFFFAOYSA-N

物化性质

• 密度：
  1.494±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  64.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  6-chloro-5-methoxy-isatin 生成 7-chloro-6-methoxy-1H-benzo[d][1,3]oxazine-2,4-dione
  参考文献：
  名称：

  1,4-苯并二氮杂3,5-二酮的合成，转化和一般药理活性。

  摘要：

  DOI：

  10.1021/jm00294a028

文献信息

• Antihypertensive 3-tetrazoyl-4-quinolones
  申请人：The Boots Company Plc

  公开号：US04659718A1

  公开（公告）日：1987-04-21

  Novel quinolones of formula I ##STR1## and pharmaceutically acceptable acid addition salts thereof in which the dotted line between positions 2 and 3 of the quinolone ring represents an optional bond, R is hydrogen, 1-methyl or 2-lower alkyl; R.sub.1 is lower alkyl; R.sub.2 is hydrogen, halo, lower alkyl, lower alkoxy, trifluoromethyl, cyano, difluoromethoxy, methylsulphinyl, phenylsulphinyl or the group --NR.sub.4 R.sub.5 or the N-oxide thereof wherein R.sub.4 and R.sub.5, which may be the same or different, are lower alkyl or, together with the nitrogen atom to which they are attached form a pyrrolidino, piperidino or morpholino radical; and R.sub.3 is hydrogen, fluoro, lower alkyl or lower alkoxy provided that, when R.sub.3 is lower alkoxy, R.sub.2 is other than lower alkoxy have utility as antihypertensive agents. Processes for preparing the quinolones and pharmaceutical compositions containing them are disclosed.

  式I所示的新奎诺酮化合物及其药学上可接受的酸盐，其中奎诺酮环的2和3号位置之间的虚线表示可选键，R为氢、1-甲基或2-较低烷基；R.sub.1为较低烷基；R.sub.2为氢、卤素、较低烷基、较低烷氧基、三氟甲基、氰基、二氟甲氧基、甲基磺酰基、苯基磺酰基或--NR.sub.4R.sub.5 或其N-氧化物，其中R.sub.4和R.sub.5，可以相同也可以不同，为较低烷基或与它们连接的氮原子形成吡咯烷基、哌啶烷基或吗啉基；R.sub.3为氢、氟、较低烷基或较低烷氧基，但当R.sub.3为较低烷氧基时，R.sub.2不为较低烷氧基，具有降压作用。公开了制备奎诺酮化合物的过程和含有它们的药物组合物。
• Therapeutic agents
  申请人：The Boots Company PLC

  公开号：EP0135367A1

  公开（公告）日：1985-03-27

  Novel quinolones of formula I and pharmaceutically acceptable acid addition salts thereof in which the dotted line between positions 2 and 3 of the quinolone ring represents an optional bond, R is hydrogen, 1-methyl or 2-lower alkyl; R, is lower alkyl; R2 is hydrogen, halo, lower alkyl, lower alkoxy, trifluoromethyl, cyano, difluoromethoxy, methylsulphinyl, phenylsulphinyl or the group -NR4R5 or the N-oxide thereof wherein R4 and R5, which may be the same or different, are lower alkyl or, together with the nitrogen atom to which they are attached form a pyrrolidino, piperidino or morpholino radical; and R3 is hydrogen, fluoro, lower alkyl or lower alkoxy provided that, when R3 is lower alkoxy, R2 is other than lower alkoxy have utility as antihypertensive agents. Processes for preparing the quinolones and pharmaceutical compositions containing them are disclosed.

  式 I 的新型喹诺酮类药物 及其药学上可接受的酸加成盐，其中喹诺酮环的位置2和3之间的虚线代表任选键，R是氢、1-甲基或2-低级烷基；R，是低级烷基；R2是氢、卤素、低级烷基、低级烷氧基、三氟甲基、氰基、二氟甲氧基、甲基亚磺酰基、苯基亚磺酰基或基团 -NR4R5 或其 N-氧化物，其中 R4 和 R5（可以相同或不同）是低级烷基，或与所连接的氮原子一起形成吡咯烷基、哌啶基或吗啉基；R3是氢、氟、低级烷基或低级烷氧基，但当R3是低级烷氧基时，R2是低级烷氧基以外的基团。本研究还公开了制备喹诺酮类药物和含有它们的药物组合物的工艺。
• US4659718A
  申请人：——

  公开号：US4659718A

  公开（公告）日：1987-04-21